The Pan-Asian pharmaceutical, biotech and healthcare spheres have seen a rise in cross-border alliances and acquisitions leading to a new era of convergence. The market for such deals is broad-based and likely to remain brisk into 2011-12, impacting the patent access and funds dynamic across the globe. Spurred by the need for improved efficiencies, lower risk-taking and greater innovation, decision makers in all domains of pharmaceuticals, biotech and life sciences are looking to Asian markets for strategic alliances or buy-outs as valuable entry points into an increasingly competitive, yet convergent, global eco-system.
With mounting pressure on ROIs in R&D, looming patent expirations, greater demand from a more affluent Asian middle class, and greater access to emerging markets in Asia, convergence seems like a natural response to tap into improved market and production efficiencies.
A unique twist however has been the rising influence of Asian funds on global transactions. Funds from private investment groups and companies in Malaysia, India, China, Japan and Korea have been making headlines not only for the value of the deals, but also for the strategic nature the deal's bandwidth, causing a significant paradigm shift in global access dynamics.
Just as Asian private firms from biotech, pharmaceuticals and biopharma expand their market peripheries both geographically and in terms of patent-product space, governments are joining the push-out through legislative and infrastructure responses.
In the end, as in all alliances and M&A, leveraging any anticipated competitive advantage is key, and sustainability is paramount. GHC 2011 examines trends, opportunities and key challenges in the transformation of the Asian pharmaceutical, biotech and healthcare sphere.
See you at GHC 2011!
"On behalf of Magenta Global, I am delighted to announce the 3rd Annual Global Healthcare Congress 2011.
GHC is rapidly building itself as the premier knowledge transfer platform for healthcare and pharma/biotech professionals looking at business drivers. Over the years, the Congress has become recognized for its timely discussions, knowledgeable speaker panel, and great networking!"
|
Healthcare operators, providers and management organizations; pharmaceutical, biotech, diagnostics and medical services companies; healthcare and speciality practice associations; regulatory boards and policy makers; academic and research institutions; institutional investors, asset management and hedge funds; private equity and venture capital; financial consulting, legal advisory and other ancillary services.
CEOs and Managing Partners, Chief Investment Officers, Vice Presidents and Directors, Business Heads and other senior executives handling mergers & acquisitions, corporate finance, investment banking, corporate strategy and planning, treasury and business development.
Exclusive interviews with our Speakers pre and onsite!
Members of the media are invited to send us questions on this topic for exclusives with GHC 2011 speakers at or ahead of the event. Send your name, designation, publication, DID and work email address along with your questions to media@magenta-global.com.sg.
|
|
